Presentation is loading. Please wait.

Presentation is loading. Please wait.

Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,

Similar presentations


Presentation on theme: "Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,"— Presentation transcript:

1 Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods, MSc, Neil Hawkins, PhD, William Dunlop, MEc, Alison O'Toole, MB BS, FRCA, PhD, MFPM, Steve Bramham-Jones, DipAM Value in Health Volume 15, Issue 5, Pages 759-770 (July 2012) DOI: 10.1016/j.jval.2012.03.1389 Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions

2 Fig. 1 Value in Health 2012 15, 759-770DOI: (10.1016/j.jval.2012.03.1389) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions

3 Fig. 2 Value in Health 2012 15, 759-770DOI: (10.1016/j.jval.2012.03.1389) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions

4 Fig. 3 Value in Health 2012 15, 759-770DOI: (10.1016/j.jval.2012.03.1389) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions

5 Fig. 4 Value in Health 2012 15, 759-770DOI: (10.1016/j.jval.2012.03.1389) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions

6 Fig. 5 Value in Health 2012 15, 759-770DOI: (10.1016/j.jval.2012.03.1389) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions

7 Fig 6 Value in Health 2012 15, 759-770DOI: (10.1016/j.jval.2012.03.1389) Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions Terms and Conditions


Download ppt "Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,"

Similar presentations


Ads by Google